The novelty of our previous article published 2005 was to show the high percentage of HER2 expression in urinary bladder cancers and to indicate a possible value of HER2-targeted therapy (with for example lapatinib and/or trastuzumab).22 However, since then there has been reports on resistance of urinary bladder cancer for both EGFR-and HER2-targeting agents (e.g. cetuximab, trastuzumab, lapatinib).5–8 The novelty of the present article is to suggest targeting of the receptors with agents9–12 that deliver radionuclides of therapy interest. The gene discussed is EGFR; the disease is urinary bladder cancer.